Radiation recall dermatitis induced by pazopanib

Arun Azad, Claire Maddison, Josephine Stewart

Research output: Contribution to journalArticleOtherpeer-review

12 Citations (Scopus)


Background: Pazopanib is a multi-targeted tyrosine kinase inhibitor that has recently been approved for treatment of advanced clear cell renal cell carcinoma (RCC). There are no previous reports of pazopanib triggering radiation recall dermatitis (RRD). Case Report: A 60-year-old male patient was commenced on pazopanib for metastatic RCC 2 weeks prior to receiving radiotherapy (10×30 Gy) to bone metastases at the T9 and L4 vertebrae and right mid-shaft of humerus. Although there were no immediate complications from radiotherapy, 2 weeks after finishing radiation he developed a pruritic, erythematous, maculo-papular rash localized to the T9 and right humeral radiotherapy fields. The patient was diagnosed with RRD induced by pazopanib and commenced on a course of oral prednisolone, which resulted in resolution of his rash. He has now completed 5 months of pazopanib with no recurrence of RRD. Conclusion: We report the first case of RRD triggered by pazopanib. With increasing use of pazopanib for advanced RCC, clinicians must be aware of the possibility that RRD can occur in patients treated with this agent following radiotherapy.

Original languageEnglish
Pages (from-to)674-676
Number of pages3
Issue number11
Publication statusPublished - Nov 2013
Externally publishedYes


  • Dermatitis
  • Pazopanib
  • Radiation recall
  • VEGF

Cite this